US Patent

US10406172 — Pharmaceutical composition, methods for treating and uses thereof

Method of Use · Assigned to Boehringer Ingelheim International GmbH · Expires 2030-06-15 · 4y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a pharmaceutical composition and methods for treating or preventing conditions such as type 1 and 2 diabetes mellitus.

USPTO Abstract

The invention relates to a pharmaceutical composition according to the claim 1 comprising an SGLT2 inhibitor, a DPPIV inhibitor and a third antidiabetic agent which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2733 — Jardiance
U-2733 — Jardiance
U-2733 — Jardiance
U-2733 — Jardiance

Patent Metadata

Patent number
US10406172
Jurisdiction
US
Classification
Method of Use
Expires
2030-06-15
Drug substance claim
No
Drug product claim
Yes
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.